Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements. The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings

To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:

§  Commonly Outsourced Business Operations

§  Active Pharmaceutical Ingredients (API)

§  Finished Dosage Formulations (FDF)

§  Types of Expression System

§  Mammalian

§  Microbial

§  Others

§  Company Size

§  Small

§  Mid-Sized

§  Large and Very Large

§  Scale of Operation

§  Preclinical

§  Clinical

§  Commercial

§  Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific

§  Rest of the World 

The Biopharma Contract Manufacturing Market (3^rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain:

§  3P Biopharmaceuticals

§  Abzena

§  Albany Molecular Research

§  BioVectra

§  BioXcellence (Boehringer Ingelheim)

§  Celonic

§  Charles River Laboratories

§  ChemPartner

§  Cobra Biologics

§  CordenPharma

§  Cytovance Biologics

§  GE Healthcare

§  Goodwin Biotechnology

§  Grand River Aseptic Manufacturing

§  IDT Biologika

§  KBI BioPharma

§  Kemwell Biopharma

§  LFB Biomanufacturing

§  Meridian Life Science

§  Patheon

§  Pfizer CentreOne

§  PX'Therapeutics

§  Samsung BioLogics

§  Sanofi, CEPiA

§  Thermo Fisher Scientific

§  Vetter Pharma International

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Competitive Landscape

5. Biopharmaceutical Contract Manufacturing in North America

6. Biopharmaceutical Contract Manufacturing in Europe

7. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

8. Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World

9. Case Study: Outsourcing of Biosimilars

10. Case Study: Comparison of Small Molecule and   Large Molecule Drugs / Therapies

11. Case Study on In-House Manufacturing

12. Collaborations

13. Recent Developments

14. Capacity Analysis

15. Demand Analysis

16. Market Forecast

17. SWOT Analysis

18.  Future of The Biopharmaceutical CMO Market

19.  Survey Analysis

20. Interview Transcripts

21. Appendix 1: List of Non-Industry Players

22. Appendix 1: List of Non-Industry Players

23. Appendix 3: List of Companies and Organizations

To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com